Why the study?
The study was conducted to assess the frequency of individual NOAC use and identify factors predisposing to their prescription among patients ≥75 years with atrial fibrillation.
What factors determine the selection of individual NOACs (apixaban, dabigatran, rivaroxaban) in hospitalized elderly patients (≥75 years) with non-valvular atrial fibrillation?
What factors determine the selection of individual NOACs (apixaban, dabigatran, rivaroxaban) in hospitalized elderly patients (≥75 years) with non-valvular atrial fibrillation?
In elderly patients (≥75 years) with non-valvular AF, dabigatran was the most frequently prescribed NOAC, with specific patient factors like age, bleeding history, and hypertension driving the choice of specific agents.
Answers are grounded in this paper and cite their sources.
Real-world NOAC selection in elderly AF warrants caution; leaves open optimal agent choice versus randomized evidence.
BACKGROUND: Atrial fibrillation (AF) is the most common disease in elderly patients and thromboembolic complication prophylaxis significantly improves the prognosis in these patients. The study assessed the frequency of individual non-vitamin K antagonist oral anticoagulant (NOAC) use among patients ≥75 years and attempted to identify factors predisposing to their prescription. METHODS: The data of patients with non-valvular AF hospitalized in the reference cardiology center between 2011 and 2019 were analyzed. RESULTS: Out of 1443 analyzed patients, 329 (22.8%) received apixaban, 618 (42.8%) dabigatran, and 496 (34.4%) rivaroxaban. The entire population mean age was 82.3 ± 5 years, and 57.9% were females. Independent predictors of apixaban use were age, and bleeding history. Hospitalization for the implantation/reimplantation of a cardiac implantable electronic device (CIED) reduced the chance of apixaban use. Hypertension was a predictor of dabigatran prescription. The chance of using dabigatran decreased with age. Hypertension and bleeding history decreased the chance of rivaroxaban application. CONCLUSIONS: In hospitalized AF patients ≥75 years, dabigatran was the most frequently used NOAC. Age, comorbidities and bleeding risk determined the selection of individual NOACs.
No takes yet. Share an insight, caveat, or question.
Bielecka et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: